The orthopedic elite celebrated a banner year in fiscal 2023; no company in the top 10 list reported revenue loss. The reason cited by most was the long-heralded return of elective surgery pacing, after the pandemic caused a dearth in those procedures.

Smith+Nephew has formed a global Advisory Board—within the framework of its new Orthopaedics for All initiative—to boost diversity in the industry. The board will strive to build equity, break biases, and inspire inclusion for individuals wishing to pursue careers in orthopedic surgery. There is a significant disparity of women in orthopedic surgery compared to men. According to multiple studies, only 15% of all orthopedic residents were women and just 7.4% were practicing orthopedic surgeons in the United States during 2022. Several factors may contribute to this inequity including greater vulnerability to work-family conflict, less supportive references than their male counterparts, and less national research funding compared to men. Smith+Nephew aims to address these long-standing challenges headfirst and help set new standards in patient-centric care.

Earlier this week, Reinhardt and four other patients with artificial ankles shared their experiences at a town-hall-style summit held at Stryker Corp.’s Arlington campus. The event featured an array of patients from Reinhardt to a local cyclist and former police-department leader who needed the procedure to continue exercising.

Biomimetic Innovations Ltd today announced that OsStic® has been granted ‘Breakthrough Device’ designation by the FDA. The proposed indication statement for this novel new technology is: OsStic® Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.

The company’s transformation into a global player is a testament to entrepreneurial spirit, technological innovation, and dedication to customer service.

FDA greenlights medical device to combat bladder issues In the latest edition of STAT's Health Tech newsletter: the FDA greenlights device to combat bladder issues and telehealth companies court payers looking for weight loss programs.

Researchers at the University of Leeds in the UK have developed a magnetic tentacle robot that is intended for use in minimally invasive medical procedures, such as the treatment of tumors in the lungs.

Moximed, a medtech company based in California, has developed the MISHA knee system, an implantable shock absorber for use in patients with knee osteoarthritis.

The FDA issued healthcare providers updated guidance for certain warning language with paclitaxel-coated devices that treat PAD.

“It’s a setback in patient safety and surveillance,” one expert said, "and will leave us with an insufficient regulatory system for identifying unsafe devices."

The company announced the first-in-human implant of its Masa valve, saying the device could be a significant improvement in the treatment of pediatric cardiovascular congenital heart defects.

The device is indicated for both anatomic and reverse total shoulder arthroplasty.

Cala Health recently launched its kIQ system — which it calls the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with essential tremor and Parkinson’s disease.

IME East panel to explore the issues of attracting younger workers to the dynamic, high-tech manufacturing sector.